KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Accounts Payables (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Accounts Payables for 7 consecutive years, with $3.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Accounts Payables fell 94.13% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Jun 2025, down 94.13%, and an annual FY2024 reading of $5.2 million, up 19.88% over the prior year.
  • Accounts Payables was $3.3 million for Q2 2025 at Aurinia Pharmaceuticals, down from $5.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $56.8 million in Q3 2024 and bottomed at $3.3 million in Q2 2025.
  • Average Accounts Payables over 5 years is $32.9 million, with a median of $34.9 million recorded in 2021.
  • The sharpest move saw Accounts Payables skyrocketed 82.7% in 2022, then tumbled 94.13% in 2025.
  • Year by year, Accounts Payables stood at $34.9 million in 2021, then increased by 14.43% to $40.0 million in 2022, then tumbled by 89.18% to $4.3 million in 2023, then rose by 19.88% to $5.2 million in 2024, then crashed by 36.15% to $3.3 million in 2025.
  • Business Quant data shows Accounts Payables for AUPH at $3.3 million in Q2 2025, $5.2 million in Q4 2024, and $56.8 million in Q3 2024.